Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential sunitinib and everolimus for advanced renal cell carcinoma
ACTRN12609000643279Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib and everolimus in renal cell carcinoma (RCC), sponsored by The University of Sydney. Primary endpoint: Proportion of patients alive and progression-free at 6 months. Started Sep 2010; status: completed.
02
Drugs
sunitinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12609000643279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000643279.